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Tara K Sigdel1, Carrie D Nicora2, Szu-Chuan Hsieh1, Hong Dai1, Wei-Jun Qian2, David G Camp II2*
and Minnie M Sarwal1*Abstract
Analysis of native or endogenous peptides in biofluids can provide valuable insights into disease mechanisms.
Furthermore, the detected peptides may also have utility as potential biomarkers for non-invasive monitoring of
human diseases. The non-invasive nature of urine collection and the abundance of peptides in the urine makes
analysis by high-throughput ‘peptidomics’ methods , an attractive approach for investigating the pathogenesis of
renal disease. However, urine peptidomics methodologies can be problematic with regards to difficulties associated
with sample preparation. The urine matrix can provide significant background interference in making the analytical
measurements that it hampers both the identification of peptides and the depth of the peptidomics read when
utilizing LC-MS based peptidome analysis. We report on a novel adaptation of the standard solid phase extraction
(SPE) method to a modified SPE (mSPE) approach for improved peptide yield and analysis sensitivity with LC-MS
based peptidomics in terms of time, cost, clogging of the LC-MS column, peptide yield, peptide quality, and
number of peptides identified by each method. Expense and time requirements were comparable for both SPE and
mSPE, but more interfering contaminants from the urine matrix were evident in the SPE preparations (e.g., clogging
of the LC-MS columns, yellowish background coloration of prepared samples due to retained urobilin, lower
peptide yields) when compared to the mSPE method. When we compared data from technical replicates of 4 runs,
the mSPE method provided significantly improved efficiencies for the preparation of samples from urine (e.g., mSPE
peptide identification 82% versus 18% with SPE; p = 8.92E-05). Additionally, peptide identifications, when applying
the mSPE method, highlighted the biology of differential activation of urine peptidases during acute renal transplant
rejection with distinct laddering of specific peptides, which was obscured for most proteins when utilizing the conventional
SPE method. In conclusion, the mSPE method was found to be superior to the conventional, standard SPE method for
urine peptide sample preparation when applying LC-MS peptidomics analysis due to the optimized sample clean up that
provided improved experimental inference from the confidently identified peptides.
Keywords: Urine, Biomarker, Peptidomics, Biomarker discovery, Proteomics, TransplantationBackground
Disease specific biomarkers remain as an unmet need in
an overwhelming majority of cases for monitoring hu-
man health. Though there is an ever increasing effort to
identify specific and sensitive biomarkers for monitoring
human health and for the early detection of disease on-
set, many hurdles still exist in identifying effective bio-
markers [1]. In this context, urine could prove to be an
important proximal fluid in providing biomarkers that* Correspondence: Dave.Camp@pnnl.gov; MSarwal@psg.ucsf.edu
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reproduction in any medium, provided the orcould be tested noninvasively [2]. The choice of urine is
particularly useful in the context of kidney and urinary
system related diseases such as acute and chronic kidney
diseases, diseases with either the urinary bladder or
prostrate, and kidney transplantation [2-9]. Circulating
peptides in urine are to be considered potentially useful
as biomarkers as they are both abundant and easily ac-
cessible. Increased efforts to identify and analyze these
valuable peptides has been undertaken as they are
thought to contribute insights into disease mechanisms
as well as providing potential biomarkers for diagnosis,
prognosis, therapeutic intervention and treatment out-
come [10]. The emergence of new and sophisticatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 A comparison of SPE and mSPE methods for
urine peptide extraction
SPE method mSPE method
Sample processing time 6 h 8 h
Sample processing cost $12 $15
Peptide quantity as
measured by BCA assay
13.6 μg 1.2 μg
Sample Appearance and
Impact on LC column
Murky and clogs
LC column
Clear and no clogging
of LC column
% peptides identified
ompared to the total
identified peptides
18% 82%
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to analyze peptides in complex biological mixtures in
combination with the analysis of their degradation pat-
terns. This information may provide important clues
about underlying (patho) physiological processes [11,12].
Different technology platforms have been applied for the
study of urine proteins and peptides such as LC-ESI-MS
[13], LC-MALDI-MS [14], CE-MS [15], and SELDI-TOF
[16]. While SELDI-TOF and CE-MS are relatively easy
platforms to operate their weakness is that they do not
allow for peptide identification resulting in incomplete
biomarker discovery and identification. Our previous re-
port presented our findings that applied a LC-MALDI-
MS approach where a standard solid phase extraction
(SPE) method for peptide enrichment and purification
was utilized [14]. Unlike urine peptide analysis by
MALDI [17-19] urine peptidomics analysis by LC-MS is
highly sensitive to the presence of unidentified contami-
nants that exist in urine, which if not effectively removed
by further purification, impair the performance of the
LC-MS analysis. When the standard solid phase extrac-
tion (SPE) [20] method of urine peptide extraction and
purification was utilized for sample preparation, persist-
ing contaminants in the urine, inclusive of urobilin and
urobilinogen, clog the LC column and interfere with the
assay performance (Sigdel et al., unpublished data)
Herein we report a mandatory modification of the SPE
method, termed modified-SPE (mSPE) method, which
provides optimal peptide extraction and purification for
urinary peptide analysis by LC-MS.
Results and discussions
Comparison of urine peptide extraction by SPE and
mSPE methods
The study compared two peptide isolation methods to
isolate urine peptides for peptidome analysis by LC-MS.
The first method used hydrophilic-lipophilic-balanced
reversed-phase sorbent-based (a mixture of two mono-
mers, hydrophilic N-vinylpyrrolidone and lipophilic divi-
nylbenzene) solid phase extraction (SPE) method. The
second method is called modified SPE (mSPE). In this
second method, we used peptides isolated from SPE and
subjected them to a second step of purification using a
processed silicon carbide resin in a pH dependent man-
ner. The activation of the resin and peptide binding in-
volved a low pH buffer (pH 3.5-4) and elution is
performed with a Na-phosphate buffer (pH 12.5). The
comparison of the two methods, SPE versus mSPE, is
summarized in Table 1 and Figure 1. Both methods were
able to extract sufficient urine peptides for LC-MS ana-
lysis. The time required by each of the two methods to
isolate peptides from urine was comparable (6 h for SPE
vs 8 h for mSPE); as was the cost of supplies ($12 for
SPE and $15 for mSPE). Starting with a 10 mL volumeof pooled urine, the SPE method yielded a substantially
larger pellet when compared to the mSPE method, and
the crude analysis of the peptide content of the SPE pel-
let initially suggested that the method had a greater pep-
tide yield (13.6 μg by SPE compared to 1.2 μg by the
mSPE method). It was determined that the SPE peptide
extract contained additional contaminating pigments
and other unidentified matter that gave the SPE pellet a
yellowish color that was both murky and opaque. We
tested for any influence of the colored contaminant on
BCA assay by assaying the washed colored component
by BCA assay. We found out that the contaminant in
the wash solution had no protein and peptide in it indi-
cating there was no protein-like substance in it. This
confirmed that there was no influence of this colored
substance on BCA assay. Additionally, the SPE peptide
extract could not be processed for subsequent LC-MS
analysis as the associated contaminants clogged the ca-
pillary LC columns after only 1–3 sample injections
followed by LC gradient separations through the analyt-
ical column. Sample processing by the mSPE method,
resulted in a peptide extract that had a clear and color-
less appearance and, importantly, did not clog the LC
columns, irrespective of the number of sample injections
and LC separations, indicating that contaminants pre-
sent in the SOE-prepared urine had been effectively
removed by the mSPE method. Notably, there was a
striking difference in the peptide quality resulting from
each method. Two liquid chromatograms that compare
the peptide quality resulting from both methods are dis-
played in Figure 2. The LC chromatogram from the
mSPE method shows well-distributed peaks throughout
the LC span while the chromatogram from the SPE
method contains a large region of low intensity peaks
presumably due to the ionization suppression effect
from the contamination species.
Improved urine peptidome data quality by mSPE
modification
Using 4 technical replicates in each method, the mSPE
method identified approximately 4.5 times more peptides
Figure 1 Schematics of peptide extraction and purification strategy Urine samples were passed through a centrifugal filtration column
to separate intact (larger MW proteins) from native peptides (smaller MW peptides). The peptide fraction was subjected to solid phase
extraction (SPE) and modified SPE (mSPE) methods described in the Methods section. The resulting peptides were analyzed by LC-MS and
identified for comparison of robustness of the two isolation and purification methods.
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unique peptides from 283 unique proteins, whereas the
SPE method only identified 195 unique peptides from 61
unique proteins (Additional file 1: Figure S1). Between
both methods, a total of 1066 unique urine peptides (only
41 unique peptides were overlapping between the two
methods) were identified from 305 unique human proteins
of which the SPE method only identified 18% of total iden-
tified peptides, whereas 82% of total identified peptides
were picked up in samples processed by the mSPE
method, which is a significant enhancement in peptide
identification by the mSPE analysis method (p = 8.92E-05)
(Figure 3) (Additional file 2).
Endogenous peptides have been profiled and studied
in many health issues that include brain, kidney, and
neurological diseases [14,17,19,21-23]. Of significance,
analysis of the identified urine peptides in this study
when applying either method highlighted novel biology
in urine samples obtained from renal allograft patients
with acute allograft rejection [14,24] (Table 2). However,
the greater number of peptides identified by the mSPEmethod revealed a ladder-like pattern in the sequence of
the identified peptides, suggesting selective activation of
peptidases in urine; for example, the Alpha 1-antitrypsin
peptide pattern shown in Table 2. Even though a similar
cleavage pattern is observed for the peptides analyzed
from SPE-processed samples, the pattern displays only
an incomplete ladder. A list of the top 25 proteins based
on their peptide abundances in urine and their corre-
sponding identified peptides in each method is presented
in Table 3.
Conclusion
In conclusion, analysis of urine peptides can provide
valuable disease and renal injury specific biomarkers and
provide additional insights into the underlying (patho)
physical processes. The LC-MS approach represents a
powerful platform for peptidome analysis and allows for
significantly greater coverage of peptide identifications
than other approaches (e.g., MALDI [ref]). This study
demonstrated that exquisite attention needs to be paid
to the methodology selection for the preparation of
Figure 2 Comparison of representative chromatograms for SPE and mSPE. (A) The LC chromatogram from the SPE method contains a
large region of low intensity peaks presumably due to the ionization suppression effect from the contaminating species. (B) The LC
chromatogram from the mSPE method displays well-distributed peaks throughout the LC span.
Figure 3 Comparison of peptide and protein identifications between peptides extracted by either solid phase extraction (SPE) or
modified SPE (mSPE) methods. A total of 1066 unique urine peptides that originated from 305 unique human proteins were identified. Peptide
extract from SPE and mSPE methods yielded (A) 195 and 912 unique peptides (B) from 61 and 283 unique proteins. Among the identified
peptides 41 unique peptides from 31 unique proteins were commonly identified.
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Table 2 A ladder-like pattern was identified among the
peptides identified by mSPE method
Alpha 1-Antitrypsin Identified
in SPE
Identified
in mSPE
A.EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFS.L No Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFA.F No Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEF.A No Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAE.F Yes Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNKITPNLA.E Yes Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNKITPNL.A Yes Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNKITPN.L Yes Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNKITP.N No Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNKIT.P No Yes
A.EDPQGDAAQKTDTSHHDQDHPTFNK.I Yes Yes
A.EDPQGDAAQKTDTSHHDQDHPTFN.K Yes Yes
Fibrinogen Alpha
A.DEAGSEADHEGTHSTKRGHAKSRPV.R Yes Yes
A.DEAGSEADHEGTHSTKRGHAKSRP.V Yes Yes
A.DEAGSEADHEGTHSTKRGHAKS.R No Yes
A.DEAGSEADHEGTHSTKRGHAK.S No Yes
A.DEAGSEADHEGTHSTKRGHA.K Yes Yes
A.DEAGSEADHEGTHSTKRG.H Yes Yes
A.DEAGSEADHEGTHSTKR.G Yes Yes
A.DEAGSEADHEGTHSTK.R Yes Yes
Serum Albumin
R.DAHKSEVAHRFKDLGEENFKALV.L No Yes
R.DAHKSEVAHRFKDLGEENFKAL.V No Yes
R.DAHKSEVAHRFKDLGEENFKA.L No Yes
R.DAHKSEVAHRFKDLGEENFK.A No Yes
R.DAHKSEVAHRFKDLGEENF.K No Yes
R.DAHKSEVAHRFKDLGEEN.F No Yes
R.DAHKSEVAHRFKDLGEE.N No Yes
Osteopontin
K.AIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSHKQSRL.Y No Yes
K.AIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSHKQSR.L No Yes
K.AIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSHK.Q No Yes
K.AIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSH.K No Yes
Table 3 Comparison on performance of peptide
identification by SPE and mSPE methods
Protein Unique peptides from SPE Unique peptides from mSPE
ALBU 6 115
OSTP 3 106
A1AT 24 44
CO1A1 21 29
FIBA 24 19
ATNG 0 24
CD99 6 25
APOA4 0 25
CMGA 0 23
PIGR 11 16
VGF 5 20
TYB4 1 22
B2MG 1 22
APOA1 7 13
1C04 0 12
MOTI 0 11
GELS 1 11
SCG1 0 10
SRGN 0 12
HRG 1 10
LTBP4 0 9
THRB 0 10
UROM 10 1
FETUA 7 5
CALX 0 8
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purity samples as possible, free from the inherent con-
taminants that exist in urine, such as urobilin, urobilino-
gen (likely contributing to the yellowish color of the
prep by the SPE method), urea, creatinine, uric acid, car-
bohydrates, hormones, fatty acids, pigments, and inor-
ganic ions. The novel modification of the SPE method
followed by a second step that further purifies urine
peptides using processed silicon carbide in a pH-
dependent manner highlighted here allowed for prepar-
ation of a purified urine samples for optimal LC-MS
urine peptidome analysis and represents an excellent re-
placement for the standard SPE method currently used.Since this report is based on the observation that was
generated from a smaller sample set for the pure pur-
pose of methodological evaluation, further application of
the mSPE method on a larger sample cohort in clinical
biomarker setting will provide the necessary clinical val-
idation and utility.
Methods
In this study we compared two peptide isolation
methods to isolate urine peptides for peptidome analysis
by LC-MS. First, we applied a centrifugal filtration
method to isolate a native, small MW (<10 kDa) peptide
fraction from urine following a protocol we developed
for sample preparation for the proteomic analysis of
urine [4]. The filtrate containing the peptide fraction
was then subjected to two separate methods for peptide
enrichment and purification. In the first method, we ap-
plied a hydrophilic-lipophilic-balanced reversed-phase
sorbent-based solid phase extraction (SPE) method. SPE used
hydrophilic-lipophilic-balanced reversed-phase sorbent-based
Sigdel et al. Clinical Proteomics 2014, 11:7 Page 6 of 8
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and lipophilic divinylbenzene) solid phase extraction.
Whereas the second method called as modified SPE
(mSPE) used peptides isolated from SPE and further
purified the peptides with a processed silicon carbide
resin in a pH dependent manner. The activation of the
resin and peptide binding involved a low pH buffer
(pH 3.5-4) and elution is performed with a Na-phosphate
buffer (pH 12.5).Study subjects and samples, urine collection, initial
processing, and storage
The study used a pool of urine samples obtained from 5
patients with biopsy confirmed [24] acute rejection of
renal allografts (AR). Overall schematics of the method
used in this study are summarized in Figure 1. Standard
methods recommended by the Human Kidney and Urine
Proteome Project (HKUPP) were followed during collec-
tion and processing of urine samples in the kidney trans-
plant clinic. In our previous report we established
protocols that allowed for stable urine collection from
multicenter clinical studies [25], where delays in storage
and processing can be encountered. With our protocols,
urine samples can be safely stored up to 1 h at room
temperature and up to 12 h at 4°C without significant
protein degradation; samples do not require the addition
of protease inhibitors to improve sample integrity if
stored at either 4°C or −80°C within 72 h of collection;
and centrifugal filtration was the optimal processing
method. Second morning void, mid-stream urine sam-
ples (50–100 mL) were collected in sterile containers
and centrifuged at 2000 × g for 20 min at room tempe-
rature within 1 h of collection. The supernatant was sep-
arated from the pellet containing any particulate matter
including cells and cell debris. The supernatant was ad-
justed to pH 7.0 with 1 M Tris–HCl and stored at −80°C
until further analysis. In order to ensure minimum im-
pact of freeze-thaw cycles, we aliquotted urine samples
into 10 mL aliquots (5–10 tubes per sample) prior to
freezing, to ensure that multiple assays could be done
without multiple freeze-thaw cycles. Our method utilizes
10 mL urine so each aliquot only needs to be thawed
once for a single experiment. At the time of peptide ex-
traction, urinary native peptides were separated from lar-
ger molecular mass intact proteins by filtering the
supernatant through Amicon Ultra centrifugal filtration
tubes (10 K molecular weight cutoff, Millipore, Bedford,
MA). A 10 mL portion of urine was centrifuged for
20 min at 3000 × g at 10°C. The filtration unit was ini-
tially washed with 10 mL of deionized water to remove
traces of glycerine by centrifuging the tube at 3000 × g
for 10 min. This was followed by the addition of 10 mL
of urine to the filter tube and centrifuged at 3000 × g for20 min. The filtrate was transferred to a 15 mL Falcon
tube and stored at −80°C until time for analysis.
Sample preparation
A pool of 5 urine samples of 20 mL each, from patients
with biopsy confirmed AR was assembled. The pooled
urine sample was split into 10–2 mL aliquots. For this
step we used 4–2 mL aliquots for the evaluation of the
SPE method and 4–2 mL aliquots for the mSPE method
that included the Proteospin column (Norgen Biotek,
Thorold, Canada).
An Oasis HLB extraction cartridge (Waters, Milford,
MA) was chosen for the initial peptide extraction. Two
mL of 100% acetonitrile were passed through the col-
umn before equilibrating with 5 mL of 0.1% trifluoroace-
tic acid (TFA) at a rate of 1 drop/s. The pH of the
peptide samples was adjusted to pH 3.0 with 50% TFA
and the peptides were then loaded onto the cartridge.
The cartridge was washed with 5 mL of 0.1% TFA
followed by elution with 1.5 mL 0.1% TFA in 70% aceto-
nitrile mixture. The elution step was repeated a second
time and the volume of the eluted peptides were brought
to 500 μL by SpeedVac concentration. The resulting
peptide mixture was then extracted with 1 mL ethyl
acetate by mixing and vortexing for 1 min and discard-
ing the upper organic layer.
Solid phase extraction (SPE)
For the SPE extraction we repeated the previously de-
scribed procedure using an Oasis HLB extraction cart-
ridge for the initial peptide extraction. Two mL of 100%
acetonitrile was passed through the column before
equilibrating with 5 mL of 0.1% trifluoroacetic acid
(TFA) at a rate of 1 drop/s. The peptide samples were
adjusted to pH 3.0 with 50% TFA and the peptides were
then loaded onto the cartridge. The cartridge was
washed with 5 mL of 0.1% TFA followed by the elution
step with 1.5 mL 0.1% TFA in 70% acetonitrile. The pep-
tide extract was aliquoted and stored at −80°C until time
for further analysis.
Enrichment of Low-MW endogenous peptides in Urine
(using ProteoSpin™ Urine Protein Concentration Micro Kit
Product-Product # 17400 (NOrgen Biotek, Thorold, Canada))
(mSPE method)
For the mSPE method, an initial peptide extraction using
an Oasis HLB extraction cartridge was executed, follo-
wed by ethyl acetate extraction method as mentioned
previously. To the peptide extract after ethyl acetate ex-
traction, we added 40 μL of pH Binding Buffer (pH 3.5)
to 200 μL of urine peptide sample to adjust to pH 3.5.
The provided spin column was assembled with a collec-
tion tube and 500 μL of Column Activation and Wash
Buffer (both ph3.5) was added to the column. The
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for 2 min at 3300 × g. The activation step was repeated a
second time and 500 μL of the pH-adjusted urine pep-
tide extract from the Oasis HLB cartridge was loaded
onto the column and centrifuged for 2 min. The peptide
extract was passed through the column, 500 μL of Col-
umn Activation and Wash Buffer was added to the col-
umn, and the column was centrifuged for 2 min. The
flow-through was discarded and the step was repeated
one more time. Before the elution step 4.65 μL of
Neutralizer was added to a fresh 1.7 mL Elution Tube
and the column was transferred to the Elution Tube.
50 μL of Elution Buffer (10 mM sodium phosphate,
pH 12.5) was added to the column and it was centri-
fuged for 2 min to elute bound peptides.
LC-MS analysis
Peptide mixtures were analyzed on a high resolution,
reversed-phase capillary LC system coupled with a
Thermo Fisher Scientific LTQ-Orbitrap Velos MS (San
Jose, CA). The automated LC system was custom built
using two Agilent 1200 nanoflow pumps and one Agi-
lent 1200 capillary pump (Agilent Technologies, Santa
Clara, CA), and a PAL autosampler (Leap Technologies,
Carrboro, NC). Full automation was made possible by
custom software that allowed for parallel event coordin-
ation and, therefore, approximately 100% of the MS duty
cycle, through the use of two trapping and analytical ca-
pillary columns, was achieved. Capillary reversed-phase
columns were prepared in-house by slurry packing 3-μm
Jupiter C18 (Phenomenex, Torrence, CA) into 35-cm ×
360 μm o.d. × 75 μm i.d fused silica (Polymicro Tech-
nologies Inc., Phoenix, AZ). Trapping columns were
prepared similarly, but using 3.6 μm Aeris Widepore
XB-C18 packed into a 4 cm length of 150 μm i.d. fused
silica. Mobile phases consisted of 0.1% formic acid in
water (A) and 0.1% formic acid acetonitrile (B) oper-
ated at constant flow of 300 nL/min with a gradient
profile over the course of 100 min as follows (min:%B);
0:5, 2:8, 20:12, 75:35, 97:60, 100:85. Sample injections
(5 μL) were trapped and washed on the trapping col-
umns at 1.5 μL/min for 20 min prior to alignment with
analytical columns. Two-column operation also allowed
for columns to be ‘washed’ (shortened gradients) and
re-generated off-line without any cost to duty cycle.
MS analysis was performed on a LTQ-Orbitrap Velos
mass spectrometer outfitted with a custom electrospray
ionization (ESI) interface. Electrospray emitters were cus-
tom made by chemically etching 150 μm o.d. × 20 μm i.d.
fused silica [25]. The heated capillary temperature and
spray voltage were 350°C and 2.2 kV, respectively. Full MS
spectra were recorded at a resolution of 100 K (for ions at
m/z 400) over the range of m/z 400–2000 with an auto-
mated gain control (AGC) value of 1e6. MS/MS wasperformed in the data-dependent mode with an AGC tar-
get value of 3e4. The ten most abundant parent ions, ex-
cluding single charge states, were selected for MS/MS
using high-energy collisional dissociation (HCD) with a
normalized collision energy setting of 40%. A dynamic ex-
clusion time of 45 s was used.
Peptide and protein identifications
LC-MS/MS raw data were converted into “.dta” files
using Extract_MSn (version 3.0) from Bioworks Cluster
3.2 (Thermo Scientific). MS/MS spectra were identified
based on database searching against a human protein data-
base (UniprotKB, released 2010–05) using both SEQUEST
(version 27, revision 12) and MS-Align + algorithms [26].
MS-Align + is an algorithm designed for intact protein
identification and is capable of identifying high mass pep-
tides from MS/MS data. Filtering criteria using either MS-
Generating Function Score (MS-GF) <1E-10 or MS-Align
false discovery rate (FDR) <0.05 were applied to ensure the
FDR of final peptide identifications were below 1% based
on a decoy database searching strategy [27].
Additional files
Additional file 1: Figure S1. (A) LC-MS chromatograms of two process
replicates of the mSPE protocol; (B) LC-MS peak intensity correlation plot
of two mSPE protocol replicates.
Additional file 2: List of 1066 peptides identified in this study.
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